株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心的外傷後ストレス障害(PTSD):パイプライン分析

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 213134
出版日 ページ情報 英文 163 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
心的外傷後ストレス障害(PTSD):パイプライン分析 Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2019
出版日: 2019年09月23日 ページ情報: 英文 163 Pages
概要

心的外傷後ストレス障害(PTSD)は、経験したか目撃した恐ろしい出来事によって引き起こされる精神衛生状態です。症状には、フラッシュバック、悪夢および重度の不安だけではなく、その出来事に関する制御できない思考が含まれます。治療には、抗うつ薬、抗不安・認識療法などが用いられます。

当レポートでは、世界における心的外傷後ストレス障害(PTSD)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

心的外傷後ストレス障害(PTSD)の概要

治療薬の開発

  • 心的外傷後ストレス障害(PTSD)向けパイプライン製品:概要
  • 心的外傷後ストレス障害(PTSD)向けパイプライン製品:比較分析

心的外傷後ストレス障害(PTSD):各企業で開発中の治療薬

心的外傷後ストレス障害(PTSD):大学/研究機関で研究中の治療薬

心的外傷後ストレス障害(PTSD):パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

心的外傷後ストレス障害(PTSD):開発中の製品の一覧(企業別)

心的外傷後ストレス障害(PTSD):研究中の製品の一覧(大学/研究機関別)

心的外傷後ストレス障害(PTSD)の開発に従事している企業

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Azevan Pharmaceuticals, Inc.
  • 分析の背景 Pharmaceutical Partners, Inc.
  • Eli Lilly and Company
  • HolsboerMaschmeyer NeuroChemie GmbH
  • Humanetics Corporation
  • Intra-Cellular Therapies, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Marinus Pharmaceuticals, Inc.
  • Neuralstem, Inc.
  • NeuroNascent, Inc.
  • Omeros Corporation
  • 大塚ホールディングス
  • Polleo Pharma Limited
  • Synchroneuron Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Turing Pharmaceuticals AG
  • Vanda Pharmaceuticals Inc.

心的外傷後ストレス障害(PTSD):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • acamprosate calcium SR
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ADX-71743
  • AM-3506
  • brexpiprazole
  • CPP-115
  • PTSD治療薬
  • CNS疾患向けFAAHを阻害する小分子
  • 不安障害向けNPSR調整薬
  • ganaxolone
  • HL-9001
  • IC-87201
  • iloperidone
  • INV-170
  • ITI-007
  • 塩酸ケタミン
  • NNI-351
  • NSI-189
  • Rycal
  • S-107
  • 中枢神経系疾患(CNS)向けGPR151を標的にした小分子
  • CNS・自己免疫疾患向けGPR83を標的にした小分子
  • PTSD向け小分子
  • CNS・代謝障害・ENT疾患向け TrkB受容体活性小分子
  • CNS向けmGluR7拮抗小分子
  • PTSD・急性ストレス障害向けmGluR7拮抗小分
  • CNS向け拮抗薬TLR-4
  • SRX-246
  • TNX-102
  • CNS疾患向けワクチン
  • ビバガトリン
  • ZL-006

心的外傷後ストレス障害(PTSD):パイプライン製品の最新動向

心的外傷後ストレス障害(PTSD):開発が休止状態の製品

心的外傷後ストレス障害(PTSD):開発が中止された製品

心的外傷後ストレス障害(PTSD)関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Anagin Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Artelo Biosciences Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Cannabis Science Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11398IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2019, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 2, 23, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Post-Traumatic Stress Disorder (PTSD) - Overview
    • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
    • Actinogen Medical Ltd
    • Addex Therapeutics Ltd
    • Amorsa Therapeutics Inc
    • Anagin Inc
    • Aptinyx Inc
    • Artelo Biosciences Inc
    • Azevan Pharmaceuticals Inc
    • Bionomics Ltd
    • Cannabis Science Inc
    • Catalyst Pharmaceuticals Inc
    • Chronos Therapeutics Ltd
    • Corcept Therapeutics Inc
    • Eli Lilly and Co
    • Embera NeuroTherapeutics Inc
    • Immodulon Therapeutics Ltd
    • Johnson & Johnson
    • Lixte Biotechnology Holdings Inc
    • NeuroNascent Inc
    • Omeros Corp
    • Otsuka Holdings Co Ltd
    • Sanofi
    • Tonix Pharmaceuticals Holding Corp
  • Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
    • (metyrapone + oxazepam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71743 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brexpiprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBISPTSD-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPP-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTDP-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IC-87201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INV-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-40411813 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KDAC-0001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midomafetamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • modafinil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNI-351 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRX-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NYX-783 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QRX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rycal - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-411298 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize GPR83 for CNS and Immunological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule To Inhibit ACSS2 for Post Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NMDA Receptor for Depression and Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GRIA1 for Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRX-246 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNX-1600 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNX-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UE-2343 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZL-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
  • Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
Back to Top